Research
Hormonal
The dual receptor agonist tirzepatide has been approved for clinical use by the FDA.
Healthcare providers can now prescribe tirzepatide as part of diabetes management.
StrongSupportsmedium confidence
a duális receptoragonisták első reprezentánsával, az FDA által klinikai alkalmazásra engedélyezett tirzepatiddal kapcsolatos első adatokra is.
Why this rating
The claim is based on regulatory approval, which is a strong indicator of efficacy.
Source
Kettős inkretinterápia – új lehetőség a 2-es típusú diabetes vércukorcsökkentő kezelésében
Gábor Winkler et al. · Lege Artis Medicinae · 2022
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →